The major component of senile plaques in the brains of Alzheimer's disease patients is the amyloid peptide, which is derived from a larger amyloid precursor protein (APP). Early-onset familial Alzheimer's disease has been shown to correlate with mutations in three genes, including the APP gene. We are studying a APP -related gene,
apl-1 , in C . elegans . To identify genes that interact with
apl-1 , transgenic lines in which an
apl-1 cDNA is under the control of a neural-specific promoter (VAMP) were generated. These transgenic strains were confirmed by Western blot analysis to overexpress APL-1. The transgenic animals have several phenotypes, including sluggish movement and a flattened waveform. To identify genes that interact with
apl-1 , we mutagenized transgenic animals with EMS, and looked for reversion of the sluggish phenotype. After screening about 3,000 haploid genomes, two strains that suppress the sluggish phenotype were isolated. The
yn8 strain shows wild-type movement, while the
yn9 strain shows hyperactive movement. These possible suppressor genes are currently being mapped. The putative suppressor mutation in the
yn9 strain does not map to chromosome V or X. APL-1 does not contain the amyloid peptide. To determine whether production of amyloid peptide has any effect in C . elegans , transgenic strains containing a mouse APP cDNA under the control of the VAMP promoter were generated. The mAPP transgene is transcribed in transgenic animals as assayed by RT-PCR. Western blot analysis to determine whether the amyloid peptide is produced is underway. Several phenotypes have been characterized. The transgenic animals have an egg-laying defect, decrease in movement, and a longer defecation cycle. The huAPP cDNA was obtained recently, and similar studies will be performed.